Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS

J Pharm Biomed Anal. 2016 Jul 15:126:117-23. doi: 10.1016/j.jpba.2016.04.030. Epub 2016 Apr 20.

Abstract

A liquid chromatographic-tandem mass spectrometry (LC-MS/MS) method for the determination of taselisib (GDC-0032, RO5537381) concentrations in human plasma has been developed and validated to support bioanalysis of clinical samples. Solid phase extraction (SPE) was used to extract plasma samples (50μL) and the resulting samples were analyzed using reversed phase chromatography and mass spectrometry coupled with an atmospheric pressure chemical ionization interface. The mass analysis of taselisib was performed using multiple reaction monitoring transitions in positive ionization mode. The method was validated over the calibration curve range 0.400-400ng/mL using linear regression and 1/x(2) weighting. The within-run relative standard deviation (%RSD) ranged from 1.3 to 5.6%, while the between-run %RSD varied from 2.0 to 4.5% for LLOQ, low, medium, medium high and high QCs. The accuracy ranged from 94.7 to 100.3% of nominal for within-run and 96.0-99.0% of nominal for between-run for the same QCs. Extraction recovery of taselisib was between 83.8% and 92.9%. Stability of taselisib was established in human plasma for 977days at -20°C and -70°C and established in sample extracts for 96h when stored at 2 - 8°C. Stable-labeled internal standard was used to minimize matrix effects. Mean single dose pharmacokinetic parameters determined using this method for a phase I/II clinical trial were: Cmax=35.2ng/mL, AUC0-inf=1570ngh/mL, and T1/2=39.3h.

Keywords: Human plasma; LC–MS/MS; Solid phase extraction (SPE); Taselisib (GDC-0032, RO5537381); β-Sparing phosphoinositide 3-kinase (PI3K) inhibitor.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Validation Study

MeSH terms

  • Antineoplastic Agents / analysis
  • Antineoplastic Agents / blood*
  • Area Under Curve
  • Calibration
  • Chromatography, Liquid / methods*
  • Chromatography, Reverse-Phase / methods
  • Drug Stability
  • Drug Storage
  • Half-Life
  • Humans
  • Imidazoles / analysis
  • Imidazoles / blood*
  • Linear Models
  • Oxazepines / analysis
  • Oxazepines / blood*
  • Phosphoinositide-3 Kinase Inhibitors
  • Reproducibility of Results
  • Solid Phase Extraction / methods
  • Tandem Mass Spectrometry / methods*
  • Temperature
  • Time Factors

Substances

  • 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
  • Antineoplastic Agents
  • Imidazoles
  • Oxazepines
  • Phosphoinositide-3 Kinase Inhibitors